FMP
NASDAQ
0.485 USD
-0.005 (-1.03%)
Mr. David J. Arthur M.B.A.
Healthcare
Biotechnology
https://www.salariuspharma.com
NASDAQ
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea;...
0001615219
US79400X3052
79400X107
2450 Holcombe Boulevard
832 834 6992
US
2
Jan 29, 2015
0001615219
NASDAQ
Biotechnology
Healthcare
79400X107
US79400X3052
US
0.48
1.02
103.56k
2.09M
-
0.4303-2.68
5.7
-
-
-
-
-0.13
-
https://www.salariuspharma.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.